anti-human CD63, PE-conjugated, Clone MEM-259

Description
CD63 (LAMP-3, lysosome-associated membrane protein-3), a glycoprotein of tetraspanin family, is present in late endosomes, lysosomes and secretory vesicles of various cell types. It is also present in the plasma membrane, usually following cell activation. Hence, it has become an widely used basophil activation marker. In mast cells, however, CD63 exposition does not need their activation. CD63 interacts with integrins and affects phagocytosis and cell migration, it is also involved in H/K-ATPase trafficking regulation of ROMK1 channels. CD63 also serves as a T-cell costimulation molecule. Expression of CD63 can be used for predicting the prognosis in earlier stages of carcinomas.

Properties
The monoclonal antibody ADG5070/L (clone MEM-259) is a murine monoclonal antibody, subclass IgG₁. The antibody has been purified from ascites using protein-A affinity chromatography, Purity > 95% (by SDS-PAGE).

The antibody reacts with CD63 (LAMP-3), a 40-60 kDa tetraspan glycoprotein expressed by granulo-cytes, platelets, T cells, monocytes/macrophages and endothelial cells. Cell surface exposition of CD63 is usu¬ally activation-dependent.

Conjugation
The purified antibody is conjugated with Fluorescein-isothiocyanate (FITC) under optimum conditions. The reagent is adjusted for direct use. No reconstitution is necessary.

Presentation
Vial containing 500 µl (ADG5070) or 2 ml (ADG5070L) of purified antibody in PBS containing 1% BSA and 0.09% sodium azide (pH 7.2). The IgG concentration is 1 mg/ml. Spin the vial briefly before opening.

Storage and Stability
Store the antibody at 4°C. Avoid prolonged exposure to light. The reagent is stable until the expiry date stated on the vial label.

Applications
Flow Cytometry

Category: Research use only

Type: Antibody

Product Availability: Worldwide

Manufacturer: ImmBioMed GmbH & Co KG, Germany

For more information please click .pdf icon below.


References

1. Grützkau A and other: 2004 Sep;61(1):62-8.
2. Mantegazza AR and other: 2004 Aug 15;104(4):1183-90.
3. Pfistershammer K and other: 2004 Nov 15;173(10):6000-8.
4. Israels SJ, McMillan-Ward EM: 2005 Feb;93(2):311-8.
5. Kwon MS and other: 2007 Jul;57(1):46-53.
6. Lin D and other: 2008 Jan 22